Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial
- DOI
- 10.3389/fimmu.2026.1927990
- Published
- 2026-10-21
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1927990,
title = {Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial},
author = {Haiqi Lu and Xufei Wang and Zhuo Wang and Miaoqin Chen and Yiming Zhong and Lingfeng Ma and Wanfen Tang and Xian Wang and Guangliang Li},
year = {2026},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2026.1927990},
url = {https://doi.org/10.3389/fimmu.2026.1927990}
}RIS
TY - JOUR TI - Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial AU - Haiqi Lu AU - Xufei Wang AU - Zhuo Wang AU - Miaoqin Chen AU - Yiming Zhong AU - Lingfeng Ma AU - Wanfen Tang AU - Xian Wang AU - Guangliang Li PY - 2026 JO - Frontiers in Immunology DO - 10.3389/fimmu.2026.1927990 UR - https://doi.org/10.3389/fimmu.2026.1927990 ER -
APA
Lu, H., Wang, X., Wang, Z., Chen, M., Zhong, Y., Ma, L., Tang, W., Wang, X., & Li, G. (2026). Eribulin mesylate in combination with ivonescimab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer(EMIT): study protocol for a single-arm, multicenter clinical trial. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1927990
Source records
- crossref · retrieved 2026-11-06T23:44:16.759Z